ATE395342T1 - 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung - Google Patents

2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung

Info

Publication number
ATE395342T1
ATE395342T1 AT05786078T AT05786078T ATE395342T1 AT E395342 T1 ATE395342 T1 AT E395342T1 AT 05786078 T AT05786078 T AT 05786078T AT 05786078 T AT05786078 T AT 05786078T AT E395342 T1 ATE395342 T1 AT E395342T1
Authority
AT
Austria
Prior art keywords
carbamide
preparation
therapeutic use
phenylthiazole derivatives
phenylthiazole
Prior art date
Application number
AT05786078T
Other languages
English (en)
Inventor
Pierre Casellas
Daniel Floutard
Pierre Fraisse
Samir Jegham
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE395342T1 publication Critical patent/ATE395342T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05786078T 2004-07-09 2005-07-05 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung ATE395342T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0407695A FR2872813B1 (fr) 2004-07-09 2004-07-09 Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE395342T1 true ATE395342T1 (de) 2008-05-15

Family

ID=34948475

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05786078T ATE395342T1 (de) 2004-07-09 2005-07-05 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung

Country Status (26)

Country Link
US (1) US7767681B2 (de)
EP (1) EP1771425B1 (de)
JP (1) JP2008505872A (de)
KR (1) KR20070030271A (de)
CN (1) CN101001847A (de)
AR (1) AR054397A1 (de)
AT (1) ATE395342T1 (de)
AU (1) AU2005271130A1 (de)
BR (1) BRPI0513184A (de)
CA (1) CA2571143A1 (de)
CR (1) CR8824A (de)
DE (1) DE602005006815D1 (de)
EA (1) EA011076B1 (de)
EC (1) ECSP067110A (de)
ES (1) ES2304719T3 (de)
FR (1) FR2872813B1 (de)
IL (1) IL180284A0 (de)
MA (1) MA28734B1 (de)
MX (1) MX2007000367A (de)
NO (1) NO20070224L (de)
PE (1) PE20060487A1 (de)
TN (1) TNSN06439A1 (de)
TW (1) TW200621737A (de)
UY (1) UY29007A1 (de)
WO (1) WO2006016039A1 (de)
ZA (1) ZA200700705B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
GB0428327D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Ab Method
JP5118975B2 (ja) * 2004-12-24 2013-01-16 アストラゼネカ・アクチエボラーグ Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物
WO2007053499A2 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8067457B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2008064054A2 (en) * 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008120759A1 (ja) * 2007-03-30 2008-10-09 Japan Tobacco Inc. ウレア化合物およびその用途
CA2704684A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2010005782A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
PE20110397A1 (es) 2008-09-25 2011-07-01 Boehringer Ingelheim Int Compuestos que modulan selectivamente el receptor cb2
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
JP2013505295A (ja) 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2528604B1 (de) 2010-01-29 2017-11-22 The Regents of the University of California Acylpiperidinhemmer aus löslicher epoxidhydrolase
EP2542539B1 (de) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazolverbindungen für selektive cb2-rezeptormodulation
SG183853A1 (en) 2010-03-17 2012-10-30 Taivex Therapeutics Inc Modulators of hec1 activity and methods therefor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
CA3179059A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
CN112279748A (zh) * 2020-12-24 2021-01-29 浙江巨化技术中心有限公司 一种1,1,2,2-四氟乙烷的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2406634A1 (fr) 1977-10-19 1979-05-18 Fabre Sa Pierre Immunostimulants derives d'amino thiazoles
WO1987001706A2 (en) 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
EP0519449A1 (de) * 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl-Thiazolderivate mit asthmahemmender und entzündungshemmender Wirkung auf die Atemwegen
FR2701708B1 (fr) 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506751B1 (en) * 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US6852752B2 (en) 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
EP1344525A4 (de) 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha Anilinderivate oder ihre salze und diese enthaltende zytokinproduktion-inhibitoren
WO2003015778A1 (en) * 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002360733A1 (en) 2001-12-31 2003-07-24 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA(imn)PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
EP1624873A2 (de) * 2003-04-28 2006-02-15 AB Science Verwendung von tyrosin-kinase hemmern zur behandlung der hirnischämie
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
JP5118975B2 (ja) 2004-12-24 2013-01-16 アストラゼネカ・アクチエボラーグ Ｃｃｒ２ｂアンタゴニストとしてのヘテロ環式化合物
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL180284A0 (en) 2007-07-04
BRPI0513184A (pt) 2008-04-29
CR8824A (es) 2007-08-28
US20070179126A1 (en) 2007-08-02
AU2005271130A1 (en) 2006-02-16
FR2872813B1 (fr) 2007-01-19
MA28734B1 (fr) 2007-07-02
NO20070224L (no) 2007-04-02
UY29007A1 (es) 2006-02-24
EP1771425B1 (de) 2008-05-14
EA200700096A1 (ru) 2007-06-29
AR054397A1 (es) 2007-06-27
EP1771425A1 (de) 2007-04-11
ZA200700705B (en) 2008-06-25
JP2008505872A (ja) 2008-02-28
WO2006016039A1 (fr) 2006-02-16
MX2007000367A (es) 2007-03-27
ECSP067110A (es) 2007-01-26
CA2571143A1 (fr) 2006-02-16
ES2304719T3 (es) 2008-10-16
DE602005006815D1 (de) 2008-06-26
TW200621737A (en) 2006-07-01
PE20060487A1 (es) 2006-07-06
US7767681B2 (en) 2010-08-03
EA011076B1 (ru) 2008-12-30
FR2872813A1 (fr) 2006-01-13
TNSN06439A1 (fr) 2008-02-22
CN101001847A (zh) 2007-07-18
KR20070030271A (ko) 2007-03-15

Similar Documents

Publication Publication Date Title
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
DE502005002105D1 (de) 4-benzimidazol-2-yl-pyridazin-3-on-derivative, ihre herstellung und verwendung in arzneimitteln
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
ATE294171T1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
DE60323754D1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
DE502005006424D1 (de) Neue alkyl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
DE60305037D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
ATE412635T1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
DE602004015600D1 (de) Neue imidazolderivative, deren herstellung und deren verwendung als medikament
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
EP1551790A4 (de) Monoacylierte betulin- und dihydrobetulinderivate, deren herstellung und deren verwendung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE499351T1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung
DE602006005246D1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
DE602004028160D1 (de) (4-phenylpiperazin-1-yl)acylpiperidinderivate, deren herstellung und deren verwendung in therapeutka
ATE474840T1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties